会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Carboxyalkylcarbonyl aminoacid endopeptidase inhibitors
    • 羧基烷基羰基氨基酸内肽酶抑制剂
    • US5389610A
    • 1995-02-14
    • US849036
    • 1992-04-21
    • Bernard R. NeustadtElizabeth M. SmithMartin F. Haslanger
    • Bernard R. NeustadtElizabeth M. SmithMartin F. Haslanger
    • A61K31/34A61K31/341A61K31/343A61K31/38A61K31/381A61K31/40A61K31/403A61K31/404A61K38/22A61K38/55A61P3/00A61P9/00A61P9/12C07C233/47C07C233/63C07C235/40C07C237/12C07C237/24C07C319/20C07C323/59C07C323/60C07C323/64C07D207/325C07D209/14C07D209/18C07D217/26C07D307/68C07D307/79C07D333/38C07K5/08A61K39/02
    • C07C323/59C07C233/63C07C235/40C07C2101/08
    • Carboxyalkylcarbonyl aminoacid inhibitors of endopeptidases of the formula: ##STR1## or pharmaceutically acceptable salt thereof, wherein R.sup.1 is H, alkyl, arylalkyl, aryl or aryloxyalkyl; R.sup.2 is alkyl, alkenyl, alkynyl, alkoxy or alkylthio, wherein the alkyl portion is substituted with 0-3 substituents independently selected from the group consisting of hydroxy, alkoxy, alkoxyalkoxy, alkylthio, aryl, alkoxyalkylthio, arylalkoxy and arylalkylthio; R.sup.3 and R.sup.4 are independently alkyl or arylalkyl; or R.sup.3 and R.sup.4 together with the carbon to which they are attached form an optionally substituted 5-, 6- or 7-membered ring wherein said ring comprises 0 to 1 heteroatoms selected from the group consisting of sulfur and oxygen; R.sup.5 is H, alkyl, alkoxyalkyl, alkylthioalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, arylalkoxyalkyl or arylalkylthioalkyl; R.sup.6 is H, hydroxy, alkoxy, alkyl, arylalkoxy, alkoxyalkyl, alkylthioalkyl, arylalkoxyalkyl, arylalkylthioalkyl, aryl or heteroaryl; R.sup.7 is hydroxy, alkoxy, aryloxy, arylalkoxy, amino, alkylamino or dialkylamino; m is 0 or 1; and n is 0, 1, 2 or 3, use of the compounds, alone or in combination with an ACE inhibitor or an ANF, in the treatment of cardiovascular disorders such as hypertension, congestive heart failure, edema and renal insufficiency, use of the compounds in the treatment of nephrotoxicity and pain conditions, and pharmaceutical compositions containing said compounds are disclosed.
    • PCT No.PCT / US90 / 06655 Sec。 一九九二年四月二十一日 102(e)日期1992年4月21日PCT 1990年11月20日PCT PCT。 出版物WO91 / 07386 1991年5月30日。具有下式的内肽酶的羧基烷基羰基氨基酸抑制剂或其药学上可接受的盐,其中R 1是H,烷基,芳基烷基,芳基或芳氧基烷基; R2是烷基,烯基,炔基,烷氧基或烷硫基,其中烷基部分被独立选自羟基,烷氧基,烷氧基烷氧基,烷硫基,芳基,烷氧基烷硫基,芳基烷氧基和芳基烷硫基的0-3个取代基取代。 R3和R4独立地是烷基或芳基烷基; 或R 3和R 4与它们所连接的碳一起形成任选取代的5-,6-或7-元环,其中所述环包含0至1个选自硫和氧的杂原子; R 5是H,烷基,烷氧基烷基,烷硫基烷基,芳基,芳基烷基,杂芳基,杂芳基烷基,芳基烷氧基烷基或芳基烷硫基烷基; R6是H,羟基,烷氧基,烷基,芳基烷氧基,烷氧基烷基,烷基硫代烷基,芳基烷氧基烷基,芳基烷硫基烷基,芳基或杂芳基; R7是羟基,烷氧基,芳氧基,芳基烷氧基,氨基,烷基氨基或二烷基氨基; m为0或1; 和n为0,1,2或3,单独使用或与ACE抑制剂或ANF组合使用化合物治疗心血管疾病如高血压,充血性心力衰竭,水肿和肾功能不全的用途 公开了治疗肾毒性和疼痛病症的化合物和含有所述化合物的药物组合物。